ACM
AQST icon

Arcataur Capital Management’s Aquestive Therapeutics AQST Stock Holding History

Arcataur Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-37,000
Closed -$239K – 104
2025
Q4 		$239K Buy
+37,000
New +$231K 0.07% 96

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Arcataur Capital Management's AQST Position: Q1 2026 in Review

Arcataur Capital Management sold out of Aquestive Therapeutics (AQST) in Q1 2026, closing a stake of 37,000 shares — an estimated $239K sold.

Arcataur Capital Management first reported a position in AQST in Q4 2025 and held it in 1 quarter. The position peaked at $239K in Q4 2025. 180 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Arcataur Capital Management reported no remaining Aquestive Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Arcataur Capital Management sold 37,000 Aquestive Therapeutics shares in Q1 2026, an estimated $239K.
  • Arcataur Capital Management first reported a position in Aquestive Therapeutics in Q4 2025 and held it in 1 quarter.
  • Arcataur Capital Management's Aquestive Therapeutics position peaked at $239K in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Arcataur Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.